Leptin, Obestatin and Apelin levels in patients with obstructive sleep apnoea syndrome

Sabine Zirlik, Tabea Hauck, Florian Siegfried Fuchs, Markus Friedrich Neurath, Peter Christopher Konturek, Igor Alexander Harsch

1 Medical Department 1, Friedrich-Alexander University of Erlangen-Nuremberg, Erlangen, Germany
2 Department of Internal Medicine, Thuringia Clinic, Saalfeld, Germany

Summary

Background:
Recent studies suggest that adipose tissue hormones are involved in the pathogenesis of obstructive sleep apnoea syndrome (OSAS). The role of leptin, obestatin and apelin still needs to be established.

Material/Methods:
Ten patients with newly diagnosed OSAS (AHI >10/h and ESS >10 points) were enrolled in the study as well as ten healthy volunteers as controls. All underwent measurements for Leptin, Obestatin and Apelin in four hour intervals during diagnostic polysomnography for 24 h and the patients also three months after onset of CPAP treatment. Furthermore the HOMA-index and body composition were quantified.

Results:
Plasma apelin levels in the patients decreased under CPAP therapy, but showed no significant difference in patients and volunteers. We found a positive correlation to AHI, BMI in the therapy group at all observation points.

Leptin plasma levels were higher in the patient group and decreased after onset of CPAP therapy. Leptin plasma levels were positively correlated to the BMI, min. 02 and AHI in the patient group before therapy.

Plasma obestatin levels did not differ significantly in these three observation groups, but were partly correlated to AHI and weight in the newly diagnosed OSAS group.

Conclusions:
In agreement with previous investigations, we could demonstrate a difference in leptin plasma levels between healthy volunteers and patients with newly diagnosed OSAS. Apelin decreases under CPAP therapy, but not significantly.

Obestatin remains unchanged after onset of CPAP. We further found a linkage between leptin plasma levels and BMI, AHI and weight in the untreated patient group.

Key words: OSAS • adipose tissue hormones • CPAP therapy • apelin • obestatin • leptin

Full-text PDF: http://www.medscimonit.com/fulltxt.php?ICID=881450

Word count: 2980
Tables: 1
Figures: 3
References: 38

Author’s address: Sabine Zirlik, Medical Department 1, Friedrich-Alexander University of Erlangen-Nuremberg, Ulmenweg 18, D-91054 Erlangen, Germany, e-mail: sabine.zirlik@uk-erlangen.de
**Background**

The obstructive sleep apnoea syndrome (OSAS) is a disorder with a high prevalence characterized by an increased cardiovascular risk. Obesity and insulin resistance are typical metabolic features of OSAS. Since obesity has reached epidemic proportions globally [1] numerous efforts have been made to understand the complex mechanisms involved in the regulation of food intake, hunger, satiety, energy storage and consumption.

In the last two decades, several novel regulatory peptides such as leptin, ghrelin or adiponectin have been discovered and studied emphasizing their role in energy homeostasis. The demonstration of a possible role of some of these peptides in sleep regulation as independent effects apart from those in energy regulation was a fascinating additional finding [2,3].

Apelin is a peptide that was identified in 1998 [4]. The effect best characterized of this hormone is within the cardiovascular system. A hypotensive effect of apelin results from the activation of receptors expressed at the surface of endothelial cells [5], but the hormone has also been intrigued in angiogenesis [6]. Apelin receptors have been found within the lung [7] and Eyries et al. recently demonstrated that apelin expression was induced by hypoxia in cell cultures as well as in mice exposed to hypoxia [8].

With this in mind, we investigated, whether there might be differences in Apelin secretion in patients with OSAS compared to healthy people due to chronic nocturnal hypoxia in the first group and potential effects of CPAP therapy after reversal of these events. Since patients with OSAS are insulin-resistant [9], and insulin-induced apelin expression was recently demonstrated in adipocytes [10] the groups might have different apelin secretion in general and not only during some periods.

Another novel aminopeptide is obestatin. To date, effects on food intake, weight gain and intestinal motility have been investigated due to its encodement on the same gene as ghrelin [11]. We were particularly interested in its role in sleep regulation that has been investigated in rats [12,13], but not humans yet. To our knowledge, serial measurements of obestatin with regard to its putative role in sleep regulation were not performed. Patients with OSAS thus, served as a "biomodel" of disturbed sleep behaviour compared to healthy controls and furthermore, we investigated possible alterations of obestatin secretion after restoration of normal sleep in OSAS patients.

An interaction of apelin and obestatin with insulin resistance as a well characterized feature of OSAS patients has already been described; and we also determined their state of insulin (in)sensitivity by use of the HOMA model.

The role of leptin in OSAS has already been more precisely characterized. Fasting leptin levels in patients with OSAS decrease after initiation of CPAP (continuous positive airway pressure) treatment without changes in weight and are discussed as a respiratory stimulus [14]. With interactions between insulin resistance and leptin [15,16] as well as between leptin and apelin [7] and obestatin [12], we chose to determine serial leptin measurements as well to characterize possible interactions between these three hormones.

**Material and Methods**

**Subjects**

Ten patients (n=10, male) with newly diagnosed symptomatic obstructive sleep apnoea syndrome (apnoea-hypopnoea-index, AHI >10 per hour and Epworth-sleepiness-scale, ESS >10 points) were enrolled in the study. Obstructive apnoeas were defined as the absence of oronasal flow for at least 10s. Hypopnoeas were defined as reduction in airflow to ≤50% of the preceding stable baseline for 10s or longer together with a dip in oxygen saturation ≥4%. The mean number of apnoeas and hypopnoeas per hour of sleep was calculated as the apnoea/hypopnoea index (AHI). The Epworth-sleepiness-scale is a questionnaire to evaluate especially daytime sleepiness.

As a first step diagnostic polysomnography was performed. In this setting the degree of the OSAS and the sleep disturbance was quantified. The AHI as well as the sleep quality were assessed. Before polysomnographic measurements subjects underwent a complete medical history, clinical chemistry and physical examination. This was done to rule out serious other diseases (such as diabetes, hepatitis, cancer) and medication with an impact on insulin sensitivity, which might influence the analyses of adipocyte-derived hormones.

Three months later and having used the nCPAP therapy reliably all examinations were repeated (polysomnography under nCPAP therapy, questionnaire, clinical chemistry and DXA) and compared with the initial results.

The hormones leptin, obestatin and apelin were measured in four hour intervals (2, 6, 10 a.m. and 2, 6, 10 p.m.) including the night of diagnostic and therapeutic polysomnography. Normal sleep wake rhythms were retained, the average sleep time duration lay between six and nine hours. The light was turned off at 10 to 11 p.m., the patients were waked up at about 6 to 7 a.m.

Blood drawings were performed throughout an indwelling superficial forearm catheter to minimize the patients disturbance. In the second night a titration to find out the minimal sufficient therapeutic pressure was made. The goal was to reduce the pathologic AHI to a normal range (<5/h). Additionally as a potential marker of influence the exact body composition was measured by using DXA (Lunar Prodigy™). Before demission each patient was instructed to use the nCPAP therapy regularly each night for at least six hours to reach a therapeutic effect. To clarify CPAP adherence, the built-in data stores of the CPAP devices were read out. This allows to establish the number of days of use within the last three months and to calculate the mean duration of use per night of treatment.

Ten healthy volunteers (n=9 male and n=1 female) with no sleep disorder were recruited to serve as a control group. As the ten patients with OSAS they underwent the same examinations (DXA, clinical chemistry, questionnaire etc.). To rule out subjects with OSAS the volunteers were measured under study conditions with Apnoe Screen (ApnoeScreen Pro, VIASYS Healthcare GmbH, Leibnizstrasse 7, 97204...
Höchberg, Germany). Finally a comparison of the data of the volunteers and the patients regarding circadian rhythm of the adipocyte-derived hormones were made.

All persons studied gave written informed consent to participate in the study, the study protocol was approved by the local ethics committee.

The samples were collected in ethylenediamine tetraacetate-coated polypropylene tubes, centrifuged immediately at 3,000 rpm for 20 min at 0°C, and the clear plasma supernatant was then stored until plasma leptin, obestatin and apelin levels were measured as follows:

**Measurement of serum apelin**

Serum apelin was measured directly by a specific radioimmunoassay kit with a measurement range from 10–1280 pg/ml (Human Apelin-36 RIA kit, Phoenix Pharmaceuticals, Inc., 330 Beach Road, Burlingame, CA 94010, U.S.A.). All samples and standards were assayed in duplicate within the same assay.

**Measurement of serum obestatin**

Peripheral obestatin levels were measured using a commercial radioimmunoassay kit with a measurement range from 50–6,400 pg/ml (Human Obestatin RIA kit, Phoenix Pharmaceuticals, Inc., 330 Beach Road, Burlingame, CA 94010, U.S.A.). All samples and standards were assayed in duplicate within the same assay.

**Measurement of serum leptin**

Serum leptin levels were measured by a commercially available radioimmunoassay kit (Human Leptin RIA kit, Millipore Corporation, 290 Concord Road, Billerica, MA 01821). The sensitivity limit was 0.5 ng/mL. All samples and standards were assayed in duplicate within the same assay.

**Sleep studies**

The polysomnographies were performed according to the recommendations of the American Thoracic Society [17] and the German Sleep Society [18,19]. Sleep parameters were determined using the criteria of Rechtschaffen and Kales [20] and microarousals were defined in accordance with the definitions of the American Sleep Disorders Association (ASDA) [21]. All patients were monitored for at least 6h in our sleep laboratory. The measured parameters included submental electromyography, snoring detected by a microphone, electrocardiography, thoracic and abdominal movements, bilateral electrooculography, electroencephalography, nasal airflow measured by oronasal thermistors during diagnostic polysomnographies and by a pneumotachograph during CPAP studies and oxyhaemoglobin saturation using a finger oximeter (Microspan 3040G™, Jaeger and Toennies, Würzburg, Germany). The measured data were evaluated by the same qualified doctor.

**Results**

Patients and the healthy controls were approximately the same age (58.9±10.2 vs. 53.6±7.7, p>0.05). As to be expected for caucasian subjects the two groups differ significantly regarding weight (BMI 31.7±3.2 vs. 26.7±2.3 kg/m², p<0.05). Corresponding to this fact the patients had a significant higher percentage body fat (26.6±7.5 vs. 33.7±3.7, p<0.05). The patients before therapy had a significant higher AHI (4.7±6.0 h, p<0.05) and a lower sleep quality (ESS 11.7±1.7 vs. 5.1±2.1 points, p<0.05) compared to the healthy volunteers. In total 10 patients and 10 healthy controls were studied. From the 10 patients at the beginning 3 refused further CPAP therapy in the first 4–6 weeks due to discomfort. The remaining 7 patients applied the therapy according to the initial instructions for use (at least 6 hours per night). The patient group was measured twice: Before therapy and after three months of application of CPAP. The CPAP treatment significantly eliminated the previously observed obstructions. In consequence the initial AHI was reduced to a normal range (42.1±16.2 vs. 4.7±6.0 /h, p<0.05) and the mean SaO₂ was ensured (91.2±4.1 vs. 94.6±1.7%, p<0.05). The subjective sleepiness and sleep quality were improved (ESS 11.8±1.8 vs. 5.0±2.0, p<0.05) (Table 1).

**Table 1. Characteristics of patients and controls.**

|                     | Controls | Patients t=0* | Patients t=3** | p-value |
|---------------------|----------|---------------|----------------|---------|
| Age yrs             | 53.6±7.7 | 58.9±10.2     | 58.9±10.2      | ns      |
| BMI kg/m²           | 26.7±2.3 | 31.7±3.2      | 32.1±3.1       | <0.05   |
| ESS/h               | 5.1±2.1  | 11.7±1.7      | 5.0±2.0        | <0.05   |
| Male/female n       | 9 and 1  | 10            | 7              |         |
| AHI/h               | 2.7±3.1  | 4.0±18.9      | 4.7±6.0        | <0.05   |
| HOMA-Index          | 2.73±3.37| 19.15±29.83   | 11.62±16.36    | <0.05   |
| Body fat %          | 26.61±7.53| 33.72±3.77   | 33.33±3.04     | <0.05   |

* Characteristics of the 10 patients before therapy; ** characteristics of the 7 patients 3 months under therapy.
of them could line out significancies between patients before or under therapy and volunteers, except pO2. The healthy volunteers showed a significant higher mean pO2 in comparison to the patients with newly diagnosed OSAS (82.1±8.01 vs. 72.5±11.3, p<0.05).

Furthermore we examined any possible correlation of the parameters (pO2, pCO2, VC, FEV1, pH, age, height, weight, HOMA-Index, body fat, therapeutical pressure of CPAP, min. O2, basal O2, glucose, insulin, BMI, AHI and ESS points) to the peptide hormones (apelin, leptin, obestatin):

**Leptin** plasma levels of the patient group before therapy had at each time of the observation a significant correlation to the body mass index (pmin. 0.55; pmax. 0.69), min. O2 (pmin. –0.76; pmax. –0.58) and AHI (pmin. 0.55; pmax. 0.62). A significant correlation was found between Leptin measurements of newly diagnosed OSAS patients and weight at 2 a.m., 2, 6, 10 p.m. as well as the body fat percentage at 6, 10 a.m., 2 p.m.. In the therapy group positive significant correlations could be observed between leptin plasma levels and pH (at 2, 6, 10 a.m., 2, 6, 10 p.m.), BMC in g (at 2, 6, 10 a.m., 2, 6, 10 p.m.), body fat in% (at 6 a.m., 2 p.m.), FEV1 and VC (at 2, 6, 10 a.m., 2, 10 p.m.) and age (6, 10 a.m., 2, 10 p.m.).

Between **Apelin** plasma levels and the mentioned parameters we could not find any significances in the newly diagnosed OSAS group. In contrast the plasma apelin levels showed a significant correlation to the AHI (pmin. 0.82; pmax. 0.91), min. O2 (pmin. –0.75; pmax. –0.86) and BMI (pmin. 0.78; pmax. 0.85) in the therapy group at all observation points. Furthermore there was a significant correlation to the basal O2 (at 2, 6 p.m.), pressure and pO2 (at 2, 6, 10 a.m., 6, 10 p.m.).

**Obestatin** plasma levels were significantly correlated at time of OSAS diagnosis to AHI and weight (at 6, 10 p.m.), to body fat in% (at 2, 6 a.m., 2 p.m.), BMC in g (at 10 a.m., 2 p.m.) and pCO2 (at 6 a.m., 2 p.m.). After three months of therapy there was only a significant correlation to weight and height (at 6 a.m.).

Further we analysed the plasma levels of the three adipose tissue hormones in the three different observation groups:

**Leptin**

Controls had significant lower plasma leptin levels as the patients at time of diagnosis of OSAS at all observation points. Leptin levels decrease after 3 therapeutic months, in a significant manner at 6.00 and 10.00 a.m. (Figure 1).

**Apelin**

The mean plasma apelin levels of patients with newly diagnosed OSAS are higher than those of the patients under therapy, but failed to reach significance (Figure 2).

**Obestatin**

Plasma obestatin levels of the volunteers were higher in comparison to the patients before or after three months of therapy except at 6 and 10 p.m. (Figure 3). We also analysed correlations between the three adipose tissue hormones. We found a significant correlation between leptin and obestatin in the patient group before
and after onset of CPAP therapy (except at 2 a.m. in the CPAP group).

**Discussion**

The obstructive sleep apnoea syndrome is a common disorder in the adult population, especially in men. It is characterised by repetitive episodes of hypoxaemia caused by an obstruction of the upper airways. In consequence the patients suffer from sleep disturbance at night due to “arousals” [22]. Furthermore other diseases such as diabetes and hypertension are associated with OSAS [14,23]. Treatment with positive continuous airway pressure (CPAP therapy) can eliminate the obstructions and therefore the states of hypoxaemia [24]. Sleep quality and daytime vigilance restores and the risk of suffering from associated other diseases like hypertension, insulin resistance or cardiovascular complications, etc. is reduced. Unfortunately, besides these positive effects CPAP does not always impact on the weight of the patients, as demonstrated in our study group.

With the recent discovery of novel peptides like apelin and obestatin [25], data from animal models suggested, that some of these hormones play a role in OSAS independently of obesity. This has also been hypothesized in the case of leptin. Leptin regulates body fat mass by decreasing food intake and increasing resting energy expenditure [26]. Its production declines during starvation [27]. It is established, that leptin levels are elevated in an obese population as well as in patients with OSAS. Leptin levels decrease under CPAP therapy independently from the obesity of the patients, which can be confirmed in our study. In previous studies, leptin was already discussed as a respiratory stimulus, which has to date only been confirmed in animal models [14].

Apelin is a hormone with cardiovascular properties and impact on glucose homeostasis [28,29]. Apelin is secreted and expressed by human adipocytes and up-regulated by insulin and obesity [30]. The expression is strongly inhibited by fasting [31] and recovered after refeeding, in a similar way to insulin [30]. Several studies have demonstrated that Apelin is a potent angiogenic factor. And like other angiogenic factors the apelin gene is upregulated under hypoxia conditions [32]. In addition, inhibition of apelin signaling during frog embryonic development resulted in severe reduction in the formation of vascular structures [33]. A most recent study on the pathophysiological role played by apelin shown that intraperitoneal or intracerebroventricular injection in rats [13]. To our knowledge, data about humans with OSAS are not available. With our approach, we could not demonstrate differences in the obesin levels of our obese patient group with OSAS before and 3 months after onset of CPAP therapy. Apart from the conclusion, that there seem to be no significant direct effects of obestatin on respiratory function, these data fit well with the study of Anderwald-Stadler et al. [35], who observed almost no effects of insulin on obestatin during a clamp study in insulin-resistant humans. Patients with OSAS are typically insulin-resistant [36–38]. The small amount of an improvement of insulin sensitivity by CPAP in OSAS subjects demonstrated by our study group [36] does obviously not impact on obestatin levels.

**Conclusions**

Previous studies raised suspicion that regulatory peptides such as leptin, apelin and obestatin might play a role in the pathogenesis of OSAS. In our study we could demonstrate different plasma levels of leptin and apelin regarding OSAS patients before and after onset of CPAP therapy in comparison to healthy volunteers, but not in obestatin. Further investigations and different approaches will have to investigate, if these hormones might have direct effects on OSAS and through which signaling pathways they might exhibit their effects, or if these hormonal changes are rather associated to concomitant metabolic changes in treated OSAS patients such as a modulation of insulin sensitivity or changes in body fat distribution.

**References:**

1. http://www.who.int/dietphysicalactivity/publications/facts/obesity/en/
2. Chin K, Shimizu K, Nakamura T et al: Changes in intra-abdominal visceral fat and serum leptin levels in patients with obstructive sleep apnea syndrome following nasal continuous positive airway pressure therapy. Circulation, 1999; 100(7): 786–12
3. Harsch IA, Konturek PC, Koebnick C et al: Leptin and ghrelin levels in patients with obstructive sleep apnoea: effect of CPAP treatment. Eur Respir J. 2003; 22(2): 251–57
4. Tatamoto K, Hosoya M, Habata Y et al: Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun, 1998; 251(2): 471–76

5. Lee DK, Cheng R, Nguyen T et al: Characterization of apelin, the ligand for the APJ receptor. J Neurochem, 2008; 74(1): 34–41

6. Cox CM, D’Agostino S, Miller MK et al: Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. Dev Biol, 2006; 296(1): 177–89

7. O’Carroll AM, Selby T, Palkovits M, Lolait SJ: Distribution of mRNA encoding B57/ajp, the rat homologue of the human APJ receptor, and its endogenous ligand apelin in brain and peripheral tissues. Biochem Biophys Acta, 2006; 1792(1): 72–80

8. Eyries M, Siegfried G, Ciumas M et al: Hypoxia-induced apelin expression regulates endothelial cell proliferation and regenerative angiogenesis. Circ Res, 2006; 99(4): 432–40

9. Harsch IA, Hahn EG, Kontureck PC: Insulin resistance and other metabolic aspects of the obstructive sleep apnea syndrome. Med Sci Monit, 2005; 11(3): R270–75

10. Glassford AJ, Yue P, Sheikh AY et al: HIF-1 regulates hypoxia- and insulin-induced expression of apelin in adipocytes. Am J Physiol Endocrinol Metab, 2007; 293(5): E1590–96

11. Tang SQ, Jiang Q, Zhang YL et al: Obestatin: its physicochemical characteristics and physiological functions. Peptides, 2008; 29(4): 639–45

12. Bodouzi B, Gardi J, Hajdu I et al: Rhythms of ghrelin, leptin, and sleep in rats: effects of the normal diurnal cycle, restricted feeding, and sleep deprivation. Am J Physiol Regul Integr Comp Physiol, 2004; 287(5): R1071–79

13. Szentirmai E, Krueger J: Obestatin alters sleep in rats. Neurosci Lett, 2005; 381(1–2): 222–26

14. Ip MS, Lam K, Ho C et al: Serum leptin and vascular risk factors in obstructive sleep apnea syndrome. Chest, 2006; 130(5): 1380–86

15. Boden G, Chen X, Kolaczynski JW, Polansky M: Effects of prolonged hyperinsulinemia on serum leptin in normal human subjects. J Clin Invest, 1997; 100(5): 1153–58

16. Vgontzas AN, Papanicolaou D, Bixler EO et al: Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercortisolism. J Clin Endocrinol Metab, 2000; 85(3): 1151–58

17. American Thoracic Society: Indications and standards for use of nasal continuous positive airway pressure (CPAP) in sleep apnea syndromes. J Respir Crit Care Med, 1994; 150(6 Pt 1): 1738–45

18. Pezul T, Hajak G, Hofmann RM: Empfehlungen zur Dürchführung und Auswertung polygraphischer Ableitungen im diagnostischen Schlaflabor. EEG-EMG, 1993; 24: 65–70 [in German]

19. Ficker JH, Wiest G, Lehnhert G et al: Evaluation of an auto-CPAP device for treatment of obstructive sleep apnoea. Thorax, 1998; 53(8): 643–48

20. Rechtschaffen A, Kryger M: A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Public Health Service, US Government Printing Office, 1968

21. Bonnet M, Charley D, Carskadon MA: EEG arousals: Scoring rules and examples. Sleep, 1992; 15: 174–84

22. Hernandez C, Abreu J, Abreu P et al: Nocturnal melatonin plasma levels in patients with OSAS: the effect of CPAP. Eur Respir J, 2007; 30: 496–500

23. Tokuda F, Sandu Y, Matsui H et al: Serum Levels of Adipokcytokines, Adiponectin and Leptin, in Patients with Obstructive Sleep Apnea Syndrome. Inter Med, 2008; 47: 1845–49

24. Shapiro Gk, Shapiro GM: Factors that influence CPAP adherence: an overview. Sleep Breath, 2010; 14(4): 325–35

25. Henley DE, Buchanan F, Gibson R et al: Plasma apelin levels in obstructive sleep apnea and the effect of continuous positive airway pressure therapy. J Endocrinol, 2009; 203: 818–89

26. Ciftci TU, Kokturk O, Bukan N, Bilgihan A: Leptin and Ghrelin Levels in Patients with Obstructive Sleep Apnea Syndrome. Respiration, 2005; 72: 395–401

27. Aleman MR, Santolaria F, Batista N et al: Leptin role in advanced hung cancer: A mediator of the acute phase response or marker of the status of nutrition? Cytokine, 2002; 19: 21–26

28. Bellowsk J: Apelin and visfatin: Unique „beneficial” adipokines upregulated in obesity? Med Sci Monit, 2006; 12(6): RA112–19

29. Ladeiras-Lopes R, Ferreira-Martins J, Leite-Moreira A: The Apelinergic System: The Role Played in Human Physiology and Pathology and Potential Therapeutic Applications. Arq Bras Cardiol, 2008; 90(5): 343–49

30. Boucher J, Masri B, Daviaud D et al: Apelin, a Newly Identified Adipokine Up-Regulated by Insulin and Obesity. Endocrinology, 2005; 146: 1764–71

31. Castan-Laurell I, Vítkova M, Daviaud D et al: Effect of hypertaloric diet-induced weight loss in obese women on plasma apelin and adipose tissue expression of apelin and APJ. European Journal of Endocrinology, 2008; 158: 905–10

32. Rayalam S, Della-Fera MA, Krieg PA et al: A putative role for apelin in the etiology of obesity. Biochem Biophys Res Commun, 2008; 368: 815–19

33. Cox CM, D’Agostino SL, Miller MK et al: Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. Dev Biol, 2006; 296: 177–89

34. Reimer MK, Pacini G, Ahrén B: Dose-dependent inhibition by ghrelin of insulin secretion in the mouse. Endocrinology, 2003; 144(3): 916–21

35. Anderwald-Stadler M, Krebs M, Promintzer M et al: Plasma obestatin levels in patients with obstructive sleep apnea syndrome: the effect of CPAP treatment. J Curr Crit Care Med, 2004; 100(5): 1107–13

36. Boucher J, Masri B, Daviaud D et al: Apelin, a Newly Identified Adipokine Up-Regulated by Insulin and Obesity. Endocrinology, 2005; 146: 1764–71

37. Oelkers W, van Hooff J, Eggink W et al: Apelin and apelin receptors. Curr Opin Pharmacol, 2007; 7: 573–80

38. Harsch IA, Koebnick C, Wallaschofski H et al: Resistin levels in patients with obstructive sleep apnea syndrome: the link to subclinical inflammation?. Med Sci Monit, 2004; 10(9): CR510–15